PROTHENA CORP PLC

Prothena insider Scully flips 627k shares in 24 hours—short‑term moves, negative earnings, and biotech volatility alert investors to watch clinical milestones and market shifts.

Insider buying fuels optimism for Prothena’s antibody pipeline – William P. Scully’s 2.3% stake signals confidence and could lift stock if clinical milestones arrive.

Prothena’s C‑Suite buys shares as insider confidence spikes—Wagner’s RSU vesting and peer buys hint at a bullish outlook amid strong earnings growth.

Prothena insider William P. Scully buys 125,000 shares at $8.17, a confidence boost amid a volatile market and growing Alzheimer’s therapy prospects.

Insider options and social‑media buzz signal confidence in Prothena’s Alzheimer’s therapies, yet market volatility remains—read the full analysis for a clear investment outlook.